Metsera and Maze Therapeutics have become the second and third biotechs to complete an initial public offering (IPO) on the Nasdaq this year, raising $275 million and $140 million, respectively.

Its prospectus says that the IPO will fund phase 1 and phase ... in the footsteps of obesity drug developer Metsera and genetic medicines developer Maze Therapeutics, which filed to list on ...

Metsera (NASDAQ:MTSR) shares opened at $25.50 after being priced at $18 per share, later hitting a high of $28.87. The stock recently sold for $27.75 at around 12:45 p.m. ET. The drug developer pr ...

Metsera is a new GLP-1 player with a Phase 2b injectable and promising oral and amylin drugs in development. Learn why MTSR ...

Metsera (MTSR), which is developing ultra-long ... More on Renaissance Capital Greenwich Funds - Renaissance IPO ETF IPO: Favorable Capital Markets In 2025 Not Yet A Tailwind (Rating Downgrade ...

NEW YORK, May 12, 2025 (GLOBE NEWSWIRE) -- Metsera, Inc. (Nasdaq ... we successfully completed a $316 million IPO and continued to build on our track record of efficient and disciplined capital ...

NEW YORK, May 08, 2025 (GLOBE NEWSWIRE) -- Metsera, Inc. (Nasdaq: MTSR) (“Metsera” or the “Company”), a clinical-stage biopharmaceutical company accelerating the next generation of ...

Additionally, Metsera is accelerating its oral formulation program for MET-097o, with outcomes anticipated in late 2025. The recent $316 million IPO will support operations through 2027 as the ...

after taking into account proceeds from the IPO, compared to $352.4 million as of December 31, 2024. Based on current operating plans, Metsera estimates its existing cash and cash equivalents will ...

NEW YORK, May 12, 2025 (GLOBE NEWSWIRE) -- Metsera, Inc. (Nasdaq: MTSR), a clinical-stage biopharmaceutical ... we successfully completed a $316 million IPO and continued to build on our track record ...